UK-based Venture Life Group PLC (VLG) has acquired three products positioned for oncology support from Helsinn Healthcare SA for CHF6.0m ($6.5m).
Two of the products – Gelclair and Xonrid – are registered as self-care medical devices but distributed through healthcare professionals, while the third, Pomi-T, is a dietary
The three acquired products are:
Gelclair - a muco-adhesive oral rinse gel used for the management of painful symptoms of oral mucositis, a side effect of some cancer therapies. Marketed in 40 countries.
Xonrid - a hyaluronic acid based topical gel used for the prevention and treatment of radiation induced dermatitis. Marketed in 21 countries